Study finds important differences in the way clinicians understand and treat early menopause after breast cancer

August 13, 2013

Hormonal treatment for breast cancer causes menopause in over 80% of women in the first year of therapy, but now new research, published in the peer-reviewed journal Climacteric, has found that how these women are diagnosed and treated for menopausal symptoms can vary substantially according to which type of doctor a woman sees.

Treatment for breast cancer usually causes to suddenly enter the menopause. For these women symptoms are generally more severe, with an abrupt and early which impairs quality of life. In addition, if a woman has gone through the menopause then some breast cancer treatments, designed to block the effect of the , can make the menopausal symptoms significantly worse. Up to 20% of breast cancer patients consider stopping their breast cancer blocking hormonal treatment because of severe menopausal symptoms, putting women at greater risk of . Now a group of Australian researchers has produced new data showing how different doctors diagnose and treat menopausal symptoms. They found that there are significant differences in approach between different medical specialities, meaning that many women may not always be getting consistent treatment.

A team led by Professor Helena Teede (Monash University) sent out detailed questionnaires to 300 who work with breast cancer patients. 151 replied, including 35 endocrinologists, 36 oncologists, 35 gynaecologists, and 35 breast surgeons. 35 GPs also participated. The questionnaire presented case scenarios of women with breast cancer and asked doctors how they would diagnose and treat menopausal symptoms in these . In many cases, the differences in how doctors responded were significant. For example:

  • 43% of breast surgeons would consider prescribing HRT, which is generally considered as contraindicated in women with breast cancer, as opposed to only 17% of gynaecologists.
  • 34% of breast surgeons would consider not treating what were presented as severe menopausal symptoms at all, compared with only 6% of endocrinologists or 11% of GPs who would not treat.
  • Despite a lack of evidence of efficacy, and potential concerns around safety, around half of endocrinologists, gynaecologists, and considered recommending complementary or alternative medicine for menopausal symptoms, whereas only 9% of GPs considered this option.

The study also found that there were significant differences in how doctors decide whether a woman has entered the menopause. Absent menstrual cycles (amenorrhea) is the most common way to diagnose menopause, and was used by 86% of endocrinologists and 57% of GPs. However because of the effect of breast cancer treatments and rapid symptom onset in this population other diagnostic approaches are also used; for example all (100%) of the oncologists in the survey used blood FSH and estrogen concentration as diagnostic indicators, whereas only 46% used FSH and 9% used estrogen levels among GPs This approach of measuring hormone levels for diagnosis is not commonly used unless a woman has breast cancer, and even in this population this is just one factor which can be considered in diagnosing the menopause.

Perhaps surprisingly, the gender of the doctor also made significant differences to the diagnosis and treatment, with male clinicians more likely to prescribe no treatment, HRT, or complementary/alternative therapies than female clinicians.

Commenting on the findings, Professor Teede said:

"This is an exploratory study, which shows some encouraging results in terms of clinician awareness of menopause symptoms in this population. However, there were significant differences in approach to diagnosis and in treatment, depending on which type of clinician was responding. In addition, male doctors tended to diagnose and treat differently to female practitioners. Ideally consistency of practice and alignment with evidence based best practice is needed in this area. If not managed well, implications can include debilitating symptoms, and a negative impact on quality of life, with many women stopping important cancer treatment because of worsening .

We think this is the first study of its kind, so we need to confirm the results with larger studies in other countries. These initial findings point to the need for more awareness and education, for both affected women and doctors, and for more accessible widely understood guidelines. This work also suggests that a multidisciplinary approach to treating younger with is needed".

Explore further: Cancer survivors have more frequent and severe menopausal hot flashes

More information: Climacteric 2013;16:479-489.

Related Stories

Cancer survivors have more frequent and severe menopausal hot flashes

July 17, 2013
Women who survive cancer have more frequent, severe, and troubling hot flashes than other women with menopausal symptoms, according to a study published online today in Menopause, the journal of The North American Menopause ...

Certain breast cancers have a trait that could be attacked by new therapies

March 27, 2013
More than 100 women per day die from breast cancer in the United States. The odds of developing breast cancer increase for women taking hormone replacement therapy to avoid the effects of menopause. New research by University ...

Estrogen plus progestin use linked with increased breast cancer incidence and mortality

March 29, 2013
Estrogen plus progestin use is linked with increased breast cancer incidence. In addition, prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be ...

Sex hormones linked to breast cancer risk in women under 50

July 24, 2013
Premenopausal women with high levels of sex hormones in their blood have an increased risk of breast cancer, an Oxford University study suggests, though further research is needed to understand this link.

UK doctors urged to use preventative breast cancer drugs

June 25, 2013
Hundreds of thousands of women at high risk of developing breast cancer in Britain should be given drugs which could dramatically reduce their chances of getting the disease, doctors were advised Tuesday.

Rural women less likely to get radiation therapy after lumpectomy for breast cancer

June 24, 2013
Rural women with breast cancer are less likely than their urban counterparts to receive recommended radiation therapy after having a lumpectomy, a breast-sparing surgery that removes only tumors and surrounding tissue, a ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.